Glenmark Pharmaceuticals Ltd Share Price Today - Glenmark Pharmaceuticals Ltd Stock Price Live NSE/BSE

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK BSE: 532296

₹2136.70

(0.58%)

Tue, 10 Mar 2026, 09:55 pm

MTF 5xInvest in Glenmark Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap603.26B

PE Ratio56.64

Dividend0.23

Health Technology

Pharmaceuticals: Major

24.5K

Glenmark Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
59737.68
Net Profit
1047.14
P/B
4.91
Sector P/E
32.42
P/E
41.50
EV/EBITDA
21.14
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
15.79
ROCE
18.48
Debt/Equity
0.22
EPS (TTM)
95.92
Dividend Yield
0.12
Book Value
339.54
Interest Cover
9.56

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are thoroughly covered by earnings (12.7x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (13.5x coverage).
Dividends per share have been stable in the past 10 years.
Glenmark Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Glenmark Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Glenmark Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Glenmark Pharmaceuticals is expected to decrease over the next 2 years.
Glenmark Pharmaceuticals's earnings are expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
Glenmark Pharmaceuticals's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	46.65	46.65	46.65	46.65	46.65
FII	19.20	20.73	20.62	23.16	23.51
DII	20.09	18.61	17.64	14.60	13.85
Public	14.02	13.97	15.06	15.56	15.96
Government	0.04	0.04	0.04	0.04	0.04

Technical Analysis

RSI

68.71

MACD

41.34

50 DMA

2026.87

200 DMA

1934.52

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	2681.77	2363.97	2250.33	2046.17	1932.53	1728.37	1410.57
Fibonacci	2363.97	2242.57	2167.57	2046.17	1924.77	1849.77	1728.37
Camarilla	2224.09	2194.96	2165.83	2046.17	2107.57	2078.44	2049.30

Pivots Level: Classic

+635.60

2681.77

+317.80

2363.97

+204.17

2250.33

2046.17

Pivot Point

LTP: 2225.80

-113.63

1932.53

-317.80

1728.37

-635.60

1410.57

Moving Average

SMAEMA

Period

Value

10-EMA
2116.49
20-EMA
2079.99
30-EMA
2058.53
50-EMA
2032.33
100-EMA
1989.95
200-EMA
1899.56

Announcement Date	Purpose	Action	Ex Date
30 Jan 2026	board-meetings	Quarterly Results
14 Nov 2025	board-meetings	Quarterly Results
26 Sept 2025	dividend	₹2.50 Dividend /Share	03 Oct 2025
03 Sept 2025	dividend	Interim Dividend - Rs. - 2.5	03 Oct 2025
22 Aug 2025	agm
15 Aug 2025	dividend	Final Dividend - Rs. - 2.5	15 Sept 2025
23 May 2025	dividend	₹2.50 Dividend /Share	15 Sept 2025
30 Aug 2024	agm
13 Aug 2024	dividend	Dividend - Rs 2.50 Per Share	17 Sept 2024
24 May 2024	dividend	₹2.50 Dividend /Share	17 Sept 2024

Glenmark Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Cipla Ltd

Glenmark Pharmaceuticals Ltd About

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1977

Headquarters

CEO

Glenn Saldanha

Employees

Contact

Website

http://www.glenmarkpharma.com

complianceofficer@glenmarkpharma.com

Phone

91-22-40189999

Location

B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026

Year	History
2020	First to launch Remogliflozin + Vildagliptin FDC for Type 2 Diabetes in India. Introduced NINDANIB (Nintedanib) for Pulmonary Fibrosis in India. Introduced 400 mg strength FabiFlu for COVID-19 treatment. Received USFDA approval for Deferasirox tablets for oral suspension. Pledged 50 lakh meals amid COVID-19 pandemic. Entered exclusive licensing agreement with Hikma for Ryaltris in US.
2021	Awarded International Safety Award. Awarded Environmental, Social and Governance Summit & Awards. Launched Rufinamide Tablets USP 200 mg and 400 mg. Launched Ryaltris nasal spray in India.
2022	Received USFDA approval for Nicardipine Hydrochloride capsules. Received ANDA approval for generic birth control drug. Received India Pharma Innovation of the Year Award from Government of India. First to launch Triple FDC Teneligliptin + Pioglitazone + Metformin for Type 2 Diabetes in India. Launched Fingolimod Capsules 0.5 mg in US.
2023	Launched Bumetanide Injection USP 1 mg/4 mL and 2.5 mg/10 mL in US.
2024	Received US health regulator approval for generic stomach acid medication. Launched Lacosamide Oral Solution 10 mg/mL in US. Launched Travoprost Ophthalmic Solution USP 0.004% in US. Received ANDA approval for Topiramate Capsules USP 15 mg and 25 mg. Entered agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Sell	1510591	2173.31	11 Jul 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	1510591	2171.67	11 Jul 2025
CENTILLION RESEARCH INDIA LLP	Buy	1502024	465.46	24 Jun 2020
CENTILLION RESEARCH INDIA LLP	Sell	1502024	465.63	24 Jun 2020
GRAVITON RESEARCH CAPITAL LLP	Buy	2166286	492.61	23 Jun 2020
CENTILLION RESEARCH INDIA LLP	Buy	2431725	494.59	23 Jun 2020
SHADOWFAX ADVERTISERS PRIVATE LIMITED	Buy	3449645	500.63	23 Jun 2020
ALPHAGREP SECURITIES PRIVATE LIMITED	Buy	2918705	499.24	23 Jun 2020
HRTI PRIVATE LIMITED	Buy	1905536	498.19	23 Jun 2020
SURJECTIVE RESEARCH CAPITAL LLP	Buy	2720020	495.64	23 Jun 2020

Glenmark Pharmaceuticals Ltd News

Glenmark Gets FDA Nod for Fluticasone with 180-Day Exclusivity

Glenmark Specialty SA receives U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol with 180-day competitive generic therapy exclusivity, targeting a $520.1 million market.

04 Mar 2026

stocks

Glenmark Plans Sodium Phosphates Injection Launch

Glenmark Pharmaceuticals announces plans to launch Sodium Phosphates Injection USP in three forms starting April 2026, targeting a $66.8 million market opportunity.

27 Feb 2026

stocks

Glenmark Targets 23% EBITDA Margin, Eyes Growth

Glenmark Pharmaceuticals sets sustainable EBITDA margin target of 23% for current year and coming quarters, anticipates strong FY26 finish and launches Glenmark 3.0 growth strategy for 2027.

03 Feb 2026

stocks

Glenmark Q3 FY26 Results: Mixed Performance Amid Settlements

Glenmark Pharmaceuticals reported Q3 FY26 results with consolidated revenue of ₹39,006.15 million and net profit of ₹4,032.28 million, while standalone operations showed revenue of ₹23,599.35 million with profit of ₹2,820.66 million.

30 Jan 2026

co actions results

Glenmark Pharmaceuticals Q3FY26 Earnings Call Feb 2

Glenmark Pharmaceuticals has scheduled its Q3FY26 results earnings call for February 02, 2026, from 8:30-9:30 AM IST. The company has provided multiple dial-in numbers for global participation.

22 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800